SPH (SPH) Fair Value & Analysis
Healthcare · PL · Market cap 4.2B PLN
Fair value as of: Jun 24, 2026
From 15 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 2.96 PLN to 4.48 PLN (+51.4%) since Jun 23, 2026. Share price +8.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 6.49 PLN – 14.57 PLN · fair‑value band 3.16 PLN – 5.80 PLN · the 7.30 PLN price screens above the 4.48 PLN fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
SPH (SPH) currently trades at 7.30 PLN, while our model-based Fair Value estimate is 4.48 PLN — implying the stock looks roughly 38.6% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, SPH generated revenue of 1.4B PLN at a net margin of 5.8%. Revenue grew 7.4% year over year. It earns a return on equity of 15.5%. Net debt stands at 420M PLN. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; veterinary vaccines; and medical devices, such as gauzes, compresses, and dressing. The company also provides food supplements; medicinal and cosmetic products, including plasters, bandages, herbal cosmetics, and sanitary-hygiene products; and yophilic products, ointments, syrups, drops, suppositories, inhalers, haemodialysis concentrates, sachets, substances, infusion solutions, veterinary vaccines, solutions and chemical substances and mixtu…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SPH reported revenue of 2.6B PLN in FY2025 versus 1.6B PLN in FY2021, a compound +13.0%/yr. Reported net income was 129M PLN in FY2025, compounding +9.6%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$1,022 | R$1,243 | +22% |
| Cencora, Inc C1CO34 | R$709.32 | R$400.31 | -44% |
| Cardinal Health, Inc CAH | $216.30 | $110.75 | -49% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.6300 | -73% |
| Sitka Gold Corp SIG | A$2.76 | A$0.3300 | -88% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥45.15 | +183% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SPH (SPH) undervalued?
What is the fair value of SPH?
What is the quality score of SPH?
What is the revenue of SPH (SPH)?
What is the net profit margin of SPH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.